Although this study confirmed the role of circNINL/miR-3918/FGFR1 in LC cell lines, there is a lack of sufficient clinical experiments to validate the impact of the circNINL/miR-3918/FGFR1 axis on LC therapy. This evidence concerns the gene FGFR1 and laryngotracheoesophageal cleft.